Early downregulation of acute phase proteins after doxorubicin exposition in patients with breast cancer

[1]  J. Connor,et al.  Cytoprotective effects of ferritin on doxorubicin-induced breast cancer cell death , 2015, Oncology reports.

[2]  S. Correa,et al.  The positive is inside the negative: HER2-negative tumors can express the HER2 intracellular domain and present a HER2-positive phenotype. , 2015, Cancer Letters.

[3]  C. Panis,et al.  Breast cancer in Brazil: epidemiology and treatment challenges , 2015, Breast cancer.

[4]  R. Derynck,et al.  Signaling pathway cooperation in TGF-β-induced epithelial-mesenchymal transition. , 2014, Current opinion in cell biology.

[5]  F. López‐Soriano,et al.  Cancer cachexia: understanding the molecular basis , 2014, Nature Reviews Cancer.

[6]  S. Correa,et al.  Label-free proteomic analysis of breast cancer molecular subtypes. , 2014, Journal of proteome research.

[7]  A. Moon,et al.  Inflammatory lipid sphingosine-1-phosphate upregulates C-reactive protein via C/EBPβ and potentiates breast cancer progression , 2014, Oncogene.

[8]  J. Zarzyńska,et al.  Two Faces of TGF-Beta1 in Breast Cancer , 2014, Mediators of inflammation.

[9]  H. Kono,et al.  Molecular determinants of sterile inflammation. , 2014, Current opinion in immunology.

[10]  C. Panis.  Unraveling oxidation-induced modifications in proteins by proteomics. , 2014, Advances in protein chemistry and structural biology.

[11]  A. Moon,et al.  Inflammatory and microenvironmental factors involved in breast cancer progression , 2013, Archives of Pharmacal Research.

[12]  H. Gan,et al.  Targeting transmembrane TNF-α suppresses breast cancer growth. , 2013, Cancer research.

[13]  E. Abdelhay,et al.  How can Proteomics Reach Cancer Biomarkers , 2013 .

[14]  B. Chun,et al.  Secretory clusterin (sCLU) overexpression is associated with resistance to preoperative neoadjuvant chemotherapy in primary breast cancer. , 2013, European review for medical and pharmacological sciences.

[15]  E. Abdelhay,et al.  Putative circulating markers of the early and advanced stages of breast cancer identified by high-resolution label-free proteomics. , 2013, Cancer letters.

[16]  Shyamasree Ghosh,et al.  C-reactive protein and the biology of disease , 2013, Immunologic Research.

[17]  C. McCulloch,et al.  Multifunctional roles of gelsolin in health and diseases , 2012, Medicinal research reviews.

[18]  E. Abdelhay,et al.  Label‐free MSE proteomic analysis of chronic myeloid leukemia bone marrow plasma: disclosing new insights from therapy resistance , 2012, Proteomics.

[19]  B. Choi,et al.  Phosphoproteomic analysis of electroacupuncture analgesia in an inflammatory pain rat model. , 2012, Molecular medicine reports.

[20]  Miho Suzuki,et al.  IL-6/IL-6 receptor system and its role in physiological and pathological conditions. , 2012, Clinical science.

[21]  濱口 貴彦.  TNF inhibitor suppresses bone metastasis in a breast cancer cell line , 2012 .

[22]  A. Cecchini,et al.  Differential oxidative status and immune characterization of the early and advanced stages of human breast cancer , 2012, Breast Cancer Research and Treatment.

[23]  A. Cecchini,et al.  Oxidative stress and hematological profiles of advanced breast cancer patients subjected to paclitaxel or doxorubicin chemotherapy , 2012, Breast Cancer Research and Treatment.

[24]  Y. Shoenfeld,et al.  Antibodies against acute phase proteins and their functions in the pathogenesis of disease: a collective profile of 25 different antibodies. , 2011, Autoimmunity reviews.

[25]  D. Aggarwal,et al.  Analysis of proteome changes in doxorubicin-treated adult rat cardiomyocyte. , 2011, Journal of proteomics.

[26]  S. Garantziotis.  Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value , 2011, British Journal of Cancer.

[27]  M. Quinn,et al.  CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool? , 2009, Journal of Translational Medicine.

[28]  Liang Xiu,et al.  Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase II , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  C. Watson,et al.  Stat3 and the Inflammation/Acute Phase Response in Involution and Breast Cancer , 2009, Journal of Mammary Gland Biology and Neoplasia.

[30]  G. Chiocchia,et al.  Clusterin : A Multifacet Protein at the Crossroad of Inflammation and Autoimmunity , 2009 .

[31]  Sheng Wei,et al.  Clusterin and chemoresistance. , 2009, Advances in cancer research.

[32]  N. Stephens,et al.  Cachexia, survival and the acute phase response , 2008, Current opinion in supportive and palliative care.

[33]  E. Bruyneel,et al.  Downregulation of gelsolin family proteins counteracts cancer cell invasion in vitro. , 2007, Cancer letters.

[34]  E. Rosenne,et al.  Prophylactic IL-12 treatment reduces postoperative metastasis: mediation by increased numbers but not cytotoxicity of NK cells , 2007, Breast Cancer Research and Treatment.

[35]  L. Klotz.  Can clinically localized prostate cancer be managed conservatively? , 2005, Nature Clinical Practice Urology.

[36]  W. Sauerbrei,et al.  REporting recommendations for tumor MARKer prognostic studies (REMARK) , 2005, Nature Clinical Practice Oncology.

[37]  L. Nabors,et al.  IL‐1β induces stabilization of IL‐8 mRNA in malignant breast cancer cells via the 3′ untranslated region: Involvement of divergent RNA‐binding factors HuR, KSRP and TIAR , 2005, International journal of cancer.

[38]  L. Gianni,et al.  Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity , 2004, Pharmacological Reviews.

[39]  T. Yoshikawa,et al.  Are cytokines possible mediators of cancer cachexia? , 1996, Surgery Today.

[40]  M. Tisdale.  Pathogenesis of cancer cachexia. , 2003, The journal of supportive oncology.

[41]  Chun-Ming Huang,et al.  Proteomics reveals protein profile changes in doxorubicin--treated MCF-7 human breast cancer cells. , 2002, Cancer letters.

[42]  H. Chew.  Adjuvant therapy for breast cancer: who should get what? , 2001, Western Journal of Medicine.

[43]  J. Desborough.  The stress response to trauma and surgery. , 2000, British journal of anaesthesia.

[44]  M. Suzuki,et al.  Cytomorphometric differentiation of intraductal proliferative breast lesions , 2000, Breast cancer.

[45]  Sinha Bk,et al.  Selective formation of tumor necrosis factor-alpha (TNF) degradation products contributes to TNF mediated cytotoxicity. , 1992 .

[46]  Priestman Tj.  Results of a prospective clinical trial comparing two cytotoxic regimes containing adriamycin in women with advanced breast cancer. , 1975 .

[47]  T. Priestman.  Results of a prospective clinical trial comparing two cytotoxic regimes containing adriamycin in women with advanced breast cancer. , 1975, Clinical oncology.